TYRA Tyra Biosciences, Inc.

bullish · high conviction track record →
Get emailed when TYRA changes direction
Mkt Cap $2B 52wk $8.75 - $40.65 3h ago
Insider buying: $35,308,026 bought by 7 insiders (30d)
Factor divergence: DIVERGENCE: insider_activity bullish vs analyst_revisions bearish
Est. revisions: -0.1% (1 up, 4 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -0.8)

Factor Model

net -0.8
Est. Revisions
-0.0
Insider Activity
+0.5
Momentum
+0.0
Analyst Rev.
-0.8
Narrative Gap
+0.0

RA Capital buys $35M TYRA shares; Guggenheim starts Buy

Watch: Monitor TYRA's upcoming clinical trial data for dabogratinib to validate growth prospects and confirm Guggenheim's bullish thesis.

RA Capital Management accumulated $35.2M in TYRA shares across multiple purchases at prices between $9.63 and $16.25. Guggenheim Securities initiated TYRA coverage with a Buy rating and a $54 target on April 15, citing potential of dabogratinib and adding biopharma veteran Habib Dable to the board. Institutional ownership is strong with D.E. Shaw, Two Sigma, and Citadel participating.

Aggressive insider buying and a new high target reflect growing confidence in TYRA's lead drug and pipeline, despite recent modest insider selling and EPS estimate revisions.

Evidence

Updated Friday Insider buy by RA CAPITAL MANAGEMENT, L.P. (TYRA): $1,664,700
Updated Friday Insider buy by FUHRMAN ALAN CPA (TYRA): $151,954
Updated Friday Insider buy by RA CAPITAL MANAGEMENT, L.P. (TYRA): $19,836,066
Updated Friday Insider buy by RA CAPITAL MANAGEMENT, L.P. (TYRA): $1,904,002
Updated Friday Insider buy by RA CAPITAL MANAGEMENT, L.P. (TYRA): $11,751,304
Updated Friday Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib yahoo-finance
59d ago Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% yahoo-finance
Fundamentals & Data ▾
Tyra Biosciences, Inc. Healthcare · Biotechnology
Mkt Cap
$2B
Beta
0.96
52w Range
$8.75 - $40.65
Short Interest
8.3M 22.37%
Days to Cover
6.2 +46%
Insiders
selling 5B / 12S
EPS Estimate
$-0.59 -0.1% 30d 1up / 4dn
Est. Dispersion
14% 10 analysts
Analyst Target
$51 $37 - $60
Options P/C
0.11
Insider Cluster
strong buy 2B / 5S (officer)
Fund Convergence
strong D.E. Shaw, Two Sigma, Citadel
Top Holders
D.E. Shaw $3M
Two Sigma $2M
Citadel
Recent Filings & Data
insider trade 37
net buying · $19,618,567 sold · $35,308,026 bought
7 insiders · 37 transactions (30d)
Recent transactions
KAPLAN GILLA · exercise · $151,801
KAPLAN GILLA · sell · $528,506
HARRIS TODD JAMES · award · $52,990
FUHRMAN ALAN CPA · award · $49,839
BENSEN DANIEL · sell · $262,965
BENSEN DANIEL · sell · $228,186
MORE ROBERT J · sell · $250,000
BENSEN DANIEL · sell · $181,159
MORE ROBERT J · sell · $5,000,026
BENSEN DANIEL · sell · $2,030,923
BENSEN DANIEL · sell · $2,108,067
FUHRMAN ALAN CPA · award · $8,629
KAPLAN GILLA · sell · $93,700
KAPLAN GILLA · sell · $534,563
RA CAPITAL MANAGEMENT, L.P. · buy · $1,664,700
RA CAPITAL MANAGEMENT, L.P. · buy · $1,904,002
RA CAPITAL MANAGEMENT, L.P. · buy · $11,751,304
HARRIS TODD JAMES · award · $12,131
FUHRMAN ALAN CPA · award · $12,101
KJELLSON NINA S · sell · $74,324
KJELLSON NINA S · sell · $78,466
KJELLSON NINA S · sell · $409,645
KJELLSON NINA S · sell · $88,773
RA CAPITAL MANAGEMENT, L.P. · buy · $19,836,066
KJELLSON NINA S · sell · $1,284,133
KJELLSON NINA S · sell · $194,248
KJELLSON NINA S · sell · $2,282,656
FUHRMAN ALAN CPA · buy · $151,954
HARRIS TODD JAMES · sell · $1,711,247
HARRIS TODD JAMES · sell · $1,513,271
HARRIS TODD JAMES · sell · $12,000
HARRIS TODD JAMES · sell · $283,223
HARRIS TODD JAMES · sell · $394,441
HARRIS TODD JAMES · award · $28,674
FUHRMAN ALAN CPA · award · $20,263
KAPLAN GILLA · exercise · $37,449
BENSEN DANIEL · sell · $74,045
7 signals · latest Updated Friday

Get alerted when TYRA changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →